DURHAM, N.C. --(BUSINESS WIRE)--Apr. 9, 2021-- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced that Derek Jantz , Ph.D., Chief Scientific